Roger Mills of Addex (NASDAQ: ADXN) reports 785,976 shares and options

Rhea-AI Filing Summary

Addex Therapeutics Ltd. director and chief medical officer Roger Mills reported his initial holdings. He directly owns 785,976 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options over 50,000 shares, exercisable at $0.0640 per share.

The options began vesting in equal monthly installments over four years from the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mills Roger

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	785,976(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	01/08/2024(2)	01/07/2034	Common Stock	50,000	$0.064(3)	D

Explanation of Responses:

1. Represents 785,976 shares of Common Stock shares listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Lenaic Nathanael Teyssedou by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position does Roger Mills hold at Addex Therapeutics (ADXN)?

Roger Mills is a director and chief medical officer of Addex Therapeutics Ltd. He appears as the reporting person, indicating he holds a senior leadership role with both board and executive responsibilities at the company.

How many Addex Therapeutics (ADXN) common shares does Roger Mills report owning?

Roger Mills reports direct ownership of 785,976 shares of Common Stock. According to the disclosure, these shares are listed on the SIX Swiss Exchange, reflecting his substantial equity stake in Addex Therapeutics Ltd.

What stock options does Roger Mills hold in Addex Therapeutics (ADXN)?

Roger Mills holds stock options over 50,000 shares of Common Stock with an exercise price of $0.0640 per share. The options vest in equal monthly installments over four years starting from the exercisable date and expire on January 7, 2034.

How is the Addex Therapeutics (ADXN) stock option exercise price for Roger Mills determined?

The stock option exercise price of $0.0640 per share is reported in U.S. dollars. It reflects a conversion from Swiss francs using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.

On which exchange are Roger Mills’ Addex Therapeutics (ADXN) shares listed?

Roger Mills’ 785,976 Common Stock shares are listed on the SIX Swiss Exchange. The filing specifies that his reported common share holdings relate to shares traded on this Swiss exchange rather than on a U.S. marketplace.

How do Roger Mills’ Addex Therapeutics (ADXN) stock options vest over time?

The stock options vest in equal monthly installments over four years, starting from the exercisable date of January 8, 2024. Each vested option gives the right to purchase one ADXN share listed on the SIX Swiss Exchange.